Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of dabrafenib + trametinib in BRAF V600E-mutated rare cancers
jRCT2080223687Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2017
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib and trametinib in rare cancer, sponsored by Novartis. Started Oct 2017; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
rare cancer
Beyond the preview
Go deeper on jRCT2080223687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223687.